Medico Remedies Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics and Recent Changes

As of 30 March 2026, Medico Remedies trades at ₹33.75, down 6.3% from the previous close of ₹36.02. The stock’s 52-week range spans ₹32.11 to ₹62.00, indicating significant volatility over the past year. The company’s P/E ratio currently stands at 24.14, a level that has contributed to its upgraded valuation grade from fair to attractive. This marks a meaningful adjustment given the sector’s average and peer comparisons.

The price-to-book value ratio is 4.19, which, while elevated, remains within a range that investors find reasonable given the company’s return on equity (ROE) of 17.35% and return on capital employed (ROCE) of 15.85%. These profitability metrics underpin the valuation upgrade, signalling that the market may be undervaluing the company’s capital efficiency and earnings quality.

Peer Comparison Highlights

When compared with key peers in the Pharmaceuticals & Biotechnology sector, Medico Remedies’ valuation appears more attractive. For instance, Bliss GVS Pharma holds a P/E of 20.92 with a fair valuation grade, while Kwality Pharma is deemed expensive at a P/E of 25.42. More expensive peers include Shukra Pharma and NGL Fine Chem, with P/E ratios of 48.05 and 37.05 respectively, both rated very expensive. This context emphasises Medico Remedies’ relative value proposition despite its micro-cap status.

Additionally, the company’s EV to EBITDA ratio of 17.57 compares favourably against Shukra Pharma’s 39.37 and NGL Fine Chem’s 23.47, further supporting the notion that Medico Remedies is trading at a discount to intrinsic value relative to its operational earnings.

Stock Performance Versus Market Benchmarks

Medico Remedies’ recent stock performance has lagged broader market indices. Year-to-date, the stock has declined by 33.25%, significantly underperforming the Sensex’s 13.66% gain. Over the past one year, the stock is down 25.74%, while the Sensex has risen 5.18%. Even over a three-year horizon, Medico Remedies has declined 57.65%, contrasting with the Sensex’s 27.63% appreciation.

However, the company’s five-year return of 575% dramatically outpaces the Sensex’s 50.14%, highlighting a history of strong long-term growth despite recent setbacks. This divergence suggests that the current valuation reset may offer a buying opportunity for investors with a longer-term horizon.

Financial Efficiency and Growth Prospects

Medico Remedies’ PEG ratio of 0.78 is particularly noteworthy, indicating that the stock’s price is undervalued relative to its earnings growth potential. This contrasts with peers such as Bliss GVS Pharma (PEG 0.87) and Kwality Pharma (PEG 0.39), suggesting that Medico Remedies offers a balanced growth-to-valuation trade-off.

The company’s EV to capital employed ratio of 3.75 and EV to sales of 1.52 further reinforce the view that the stock is reasonably priced relative to its asset base and revenue generation. These metrics, combined with solid ROCE and ROE figures, highlight operational efficiency and effective capital utilisation.

Risks and Market Sentiment

Despite the attractive valuation, investors should be mindful of the stock’s recent underperformance and micro-cap classification, which can entail higher volatility and liquidity risks. The day’s trading range between ₹32.11 and ₹36.03 reflects this volatility, with a 6.3% decline signalling cautious sentiment among market participants.

Moreover, the absence of a dividend yield may deter income-focused investors, although the company’s reinvestment of earnings into growth initiatives could justify this policy.

Outlook and Investment Considerations

Medico Remedies’ recent upgrade from a sell to a hold rating, reflected in its Mojo Score of 50.0, underscores a cautious optimism among analysts. The valuation shift to attractive suggests that the stock is now more favourably priced relative to its earnings and book value, especially when viewed against sector peers and historical benchmarks.

Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may find Medico Remedies’ combination of solid profitability metrics and improved valuation compelling, particularly given its strong five-year return track record. However, the stock’s recent underperformance and micro-cap status warrant a measured approach, with attention to market volatility and company-specific developments.

In summary, the valuation realignment positions Medico Remedies as a potentially attractive candidate for investors prioritising value and growth balance within the pharmaceutical space. Monitoring upcoming quarterly results and sector trends will be crucial to validate this positive shift in price attractiveness.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →